CDX2 and cancer: Low RCC2 expression was associated with higher cancer stage in all three cohorts (p<0.001, online supplemental tables 4 and 5), but not with any other clinicopathological factors (patient age, sex or tumour location) or molecular markers (KRAS, BRAFV600E, TP53 mutation status or CDX2 expression).